Skip to main content

Table 1 Retrospective Collection of EQ-5D-5L Utility Index (US Preference Weights) and EQ VAS by Respondent Characteristics

From: Assessment of retrospective collection of EQ-5D-5L in a US COVID-19 population

 

Index Score

EQ VAS

n (%)

Mean (SD)

n (%)

Mean (SD)

All

676

0.924 (0.117)

674

87.4 (10.9)

Age

 18–34

236 (34.9)

0.916 (0.111)

236 (35.0)

88.4 (9.2)

 35–64

371 (54.9)

0.927 (0.122)

370 (54.9)

86.5 (12.1)

 65+

69 (10.2)

0.936 (0.106)

68 (10.1)

88.8 (9.2)

Gender

 Female

495 (73.2)

0.920 (0.113)

495 (73.4)

87.2 (11.1)

 Male

181 (26.8)

0.935 (0.125)

179 (26.6)

87.9 (10.3)

Race/Ethnicity

 White or Caucasian

486 (71.9)

0.921 (0.118)

484 (71.8)

87.1 (10.7)

 Black or African American

32 (4.7)

0.918 (0.166)

32 (4.8)

82.7 (14.8)

 Hispanic

85 (12.6)

0.930 (0.105)

85 (12.6)

88.4 (11.4)

 Asian

35 (5.2)

0.969 (0.051)

35 (5.2)

89.9 (9.0)

 Patient Refused

16 (2.4)

0.927 (0.096)

16 (2.4)

86.6 (10.2)

 Other

22 (3.3)

0.899 (0.131)

22 (3.3)

91.7 (9.1)

Chronic conditions

 Asthma or Chronic Lung Disease

58 (8.6)

0.873 (0.152)

57 (8.5)

81.7 (14.0)

 Diabetes

32 (4.7)

0.887 (0.131)

32 (4.8)

82.8 (11.1)

 Hypertension

76 (11.2)

0.887 (0.158)

75 (11.1)

83.1 (12.2)

 Extreme obesity

23 (3.4)

0.782 (0.258)

23 (3.4)

77.0 (13.7)

 Immunocompromised Conditions or Weakened Immune System a

27 (4.0)

0.889 (0.134)

27 (4.0)

78.6 (15.2)

  1. a Immunocompromised conditions includes compromised immune system (such as from immuno-compromising drugs, solid organ or blood stem cell transplant, HIV, or other conditions), conditions that result in a weakened immune system, including cancer treatment, and kidney failure or end stage renal disease
  2. EQ VAS = EuroQol Visual Analogue Scale